Pyxis Oncology, Inc. (PYXS) Earnings History
Net Loss7 years of earnings data (2019–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Pyxis Oncology, Inc. (PYXS) Earnings Overview
As of June 12, 2026, Pyxis Oncology, Inc. (PYXS) reported trailing twelve-month net income of -$82M, reflecting +3.0% year-over-year growth. The company earned $-1.29 per diluted share over the past four quarters, with a net profit margin of -574.5%.
Looking at the long-term picture, PYXS's historical earnings data spans multiple years. The company achieved its highest annual net income of -$3M in fiscal 2019.
Pyxis Oncology, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including IMVT (-$506M net income), RCUS (-$369M net income, -142.9% margin), TPST (-$43M net income), PYXS has comparable earnings metrics. Compare PYXS vs IMVT →
PYXS Earnings vs Peers
Earnings metrics vs comparable public companies
PYXS Historical Earnings Data (2019–2025)
7 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$80M | -3.0% | -$84M | $-1.28 | -574.5% | -609.2% |
| 2024 | -$77M | -4.8% | -$89M | $-1.32 | -478.9% | -554.1% |
| 2023 | -$74M | +38.9% | -$82M | $-1.85 | - | - |
| 2022 | -$121M | -58.9% | -$123M | $-3.57 | - | - |
| 2021 | -$76M | -492.3% | -$70M | $-2.53 | - | - |
| 2020 | -$13M | -362.8% | -$13M | $-0.37 | - | - |
| 2019 | -$3M | - | -$3M | $-0.08 | - | - |
Download Data
Export PYXS earnings history in CSV or JSON format
Free sign-in required to download data
What if you invested $1,000 in PYXS back in 2019?
Total return with dividends reinvested · 7+ years of data
Calculate ReturnsHow much would $100/month in PYXS be worth today?
Dollar cost averaging vs lump sum · see how regular investing compounds over time
Run the NumbersIs PYXS Undervalued Right Now?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationPYXS vs LLY — which is the better buy?
Side-by-side revenue, margins, P/E and 10-year returns vs Eli Lilly and Company.
Compare NowPYXS — Frequently Asked Questions
Quick answers to the most common questions about buying PYXS stock.
What is PYXS earnings per share (EPS)?
PYXS trailing twelve-month (TTM) diluted EPS is $-1.29, reflecting +3.0% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2019 to 2025 is available in the table on this page.
What is Pyxis Oncology, Inc.'s net income?
Pyxis Oncology, Inc. (PYXS) trailing twelve-month net income is $-82M as of 2025. Earnings grew +3.0% year-over-year.
Is PYXS profitable?
PYXS is not currently profitable on a TTM basis, reporting a net loss of $-82M. Net margin is -574.5%. Investors should monitor for a return to profitability.
What is PYXS's earnings growth rate?
PYXS compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2019 to 2025.
What are PYXS's profit margins?
Pyxis Oncology, Inc. net profit margin is -574.5%, operating margin is -609.2%, and gross margin is +82.8%. Below-average margins reflect competitive or cost pressures. Return on Equity is -91.4%.
Is PYXS growing earnings?
PYXS earnings growth is slowing. Current YoY EPS growth of +3.0% trails the 5-year CAGR of N/A. TTM net income is $-82M.
What was PYXS's best earnings year?
Pyxis Oncology, Inc.'s highest annual net income on record is $-3M, achieved in fiscal year 2019. Earnings history on this page spans 2019 to 2025 and includes all annual and quarterly figures.
What were PYXS's earnings last quarter?
PYXS's most recent reported quarter was Q1 2026. Net income was $-23M with diluted EPS of $-0.37. For a full breakdown of all quarters, see the quarterly earnings table on this page.